Alnylam Pharmaceuticals is an American biopharmaceutical company dedicated to the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. They pioneer a revolutionary approach to treating diseases by "silencing" the genes that cause or contribute to them. Founded in 2002, Alnylam has successfully brought multiple RNAi-based medicines to market for various conditions, including genetic, cardio-metabolic, and neurological diseases.